U.S. Markets close in 3 hrs 41 mins

AVROBIO, Inc. (AVRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.34-0.04 (-0.43%)
As of 12:19PM EDT. Market open.

AVROBIO, Inc.

Building 300
Suite 201 One Kendall Square
Cambridge, MA 02139
United States
617 914 8420
http://www.avrobio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees121

Key Executives

NameTitlePayExercisedYear Born
Mr. Geoff MacKayCo- Founder, Pres, CEO & Director811.23kN/A1966
Mr. Erik Ostrowski M.B.A.CFO & Treasurer597.08kN/A1973
Mr. Steven N. Avruch J.D.Chief Legal Officer & Sec.506.68kN/A1961
Mr. Jeffrey Medin Ph.D.Scientific FounderN/AN/AN/A
Mr. Matthew ArnoldHead of OperationsN/AN/AN/A
Mr. Kim Raineri M.B.A.Chief Manufacturing & Technology OfficerN/AN/AN/A
Dr. Christopher Mason FMEDSCI, M.D., Ph.D., FRCSChief Scientific OfficerN/AN/A1958
Ms. Monique Da SilvaSr. VP of Corp. CommunicationsN/AN/AN/A
Ms. Georgette VerdinChief HR OfficerN/AN/AN/A
Ms. Deanna M. Petersen MBAChief Bus. OfficerN/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

AVROBIO, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.